文献速递肿瘤 PET/CT核素与放射性配体治疗

开发PSMA-PET引导的CT放射组学特征预测挽救性放疗后生化复发

Development of PSMA-PET-guided CT-based radiomic signature to predict biochemical recurrence after salvage radiotherapy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-03-16

本研究为回顾性多中心研究,纳入德国三家高容量中心连续接受68Ga-PSMA11-PET/CT引导挽救性放疗的99例前列腺癌患者,均存在PET阳性局部复发并接受调强挽救性放疗。基于PSMA-PET病灶引导在CT上提取放射组学特征,构建临床、放射组学及临床-放射组学联合模型,采用嵌套交叉验证和Cox比例风险模型。放射组学模型预测生化复发的C-index为0.71,优于临床模型(0.53)和联合模型(0.63),并在Kaplan-Meier分析中实现显著更优的患者分层。

要点

  • 放射组学模型预测生化复发C-index为0.71,优于临床模型0.53和联合模型0.63。
  • 放射组学模型在Kaplan-Meier分析中实现显著改善的患者分层。
  • 平均强度是最具预测价值的放射组学特征。

核心结论

  • 这是首个开发PSMA-PET引导的CT放射组学模型预测挽救性放疗后生化复发的研究。
  • 放射组学模型优于临床模型,可能有助于指导个体化治疗决策。

研究设计与样本

  • 回顾性多中心研究,纳入德国三家高容量中心连续接受68Ga-PSMA11-PET/CT引导挽救性放疗的前列腺癌患者99例。
  • 患者均有PET阳性局部复发并接受调强挽救性放疗,从PSMA-PET局灶摄取引导的CT感兴趣体积中提取放射组学特征。
  • 预处理后,在嵌套交叉验证框架内结合不同特征降维技术和Cox比例风险模型,构建临床、放射组学及临床-放射组学联合模型。

主要发现

  • 99例患者中,放射组学模型预测生化复发的C-index为0.71,临床模型为0.53,联合模型为0.63(测试集)。
  • 与其他模型不同,放射组学模型在Kaplan-Meier分析中实现显著改善的患者分层。
  • 放射组学模型和联合模型的时间依赖净重分类改善指数分别为0.392和0.762,显著优于临床模型。
  • 决策曲线分析显示放射组学模型和联合模型均具有临床净获益。
  • 平均强度是最具预测价值的放射组学特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To develop a CT-based radiomic signature to predict biochemical recurrence (BCR) in prostate cancer patients after sRT guided by positron-emission tomography targeting prostate-specific membrane antigen (PSMA-PET). MATERIAL AND METHODS: Consecutive patients, who underwent 68Ga-PSMA11-PET/CT-guided sRT from three high-volume centers in Germany, were included in this retrospective multicenter study. Patients had PET-positive local recurrences and were treated with intensity-modulated sRT. Radiomic features were extracted from volumes of interests on CT guided by focal PSMA-PET uptakes. After preprocessing, clinical, radiomics, and combined clinical-radiomic models were developed combining different feature reduction techniques and Cox proportional hazard models within a nested cross validation approach. RESULTS: Among 99 patients, median interval until BCR was the radiomic models outperformed clinical models and combined clinical-radiomic models for prediction of BCR with a C-index of 0.71 compared to 0.53 and 0.63 in the test sets, respectively. In contrast to the other models, the radiomic model achieved significantly improved patient stratification in Kaplan-Meier analysis. The radiomic and clinical-radiomic model achieved a significantly better time-dependent net reclassification improvement index (0.392 and 0.762, respectively) compared to the clinical model. Decision curve analysis demonstrated a clinical net benefit for both models. Mean intensity was the most predictive radiomic feature. CONCLUSION: This is the first study to develop a PSMA-PET-guided CT-based radiomic model to predict BCR after sRT. The radiomic models outperformed clinical models and might contribute to guide personalized treatment decisions.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Spohn SKB, Schmidt-Hegemann NS, Ruf J, et al. Development of PSMA-PET-guided CT-based radiomic signature to predict biochemical recurrence after salvage radiotherapy. Eur J Nucl Med Mol Imaging. 2023. PMID: 36929180. doi:10.1007/s00259-023-06195-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。